Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Evogene Ltd Ord (EVGN)

Evogene Ltd Ord (EVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Evogene Ltd Ord 13 GAD FEINSTEIN STREET PARK REHOVOT REHOVOT L3 7638517 ISR

www.evogene.com Employees: 142 P: 972-8931-1900 F: 972-894-6672

Description:

Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform to develop human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production.

Key Statistics

Overview:

Market Capitalization, $K 8,692
Enterprise Value, $K -12,078
Shares Outstanding, K 5,365
Annual Sales, $ 5,640 K
Annual Net Income, $ -23,880 K
Last Quarter Sales, $ 910 K
Last Quarter Net Income, $ -5,420 K
EBIT, $ -22,000 K
EBITDA, $ -19,390 K
60-Month Beta 1.43
% of Insider Shareholders 7.40%
% of Institutional Shareholders 10.40%
Float, K 4,968
% Float 92.60%
Short Volume Ratio 0.45

Growth:

1-Year Return -72.52%
3-Year Return -90.82%
5-Year Return -87.13%
5-Year Revenue Growth 222.29%
5-Year Earnings Growth 35.80%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.06 on 08/22/24
Next Earnings Date 11/21/24
Earnings Per Share ttm -3.96
EPS Growth vs. Prev Qtr -23.58%
EPS Growth vs. Prev Year -63.75%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 07/25/24

EVGN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -95.31%
Return-on-Assets % -50.80%
Profit Margin % -423.40%
Debt/Equity 0.00
Price/Sales 1.52
Price/Cash Flow N/A
Price/Book 0.33
Book Value/Share 4.84
Interest Coverage -25.79
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar